Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,949 questions · 1,994 findings · 636 reviews

No studies found 504 · 25.3%GRADE not reported 340 · 17.1%Very low 477 · 23.9%Low 390 · 19.6%Moderate 241 · 12.1%High 42 · 2.1%

Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

It is very uncertain whether etretinate with PUVA therapy as co‐intervention changes proportion of participants with adverse effects ‐ measured over 20… compared with placebo with PUVA therapy (very low certainty).

1 finding from 1 review

Etretinate vs PUVA

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

It is very uncertain whether etretinate changes proportion of participants with adverse effects ‐ measured over 12… compared with PUVA therapy (very low certainty).

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

Alitretinoin showed no clear difference in proportion of participants with adverse effects ‐ measured over 24… compared with placebo (moderate certainty).

1 finding from 1 review

Clobazam vs phenytoin

Adverse effects requiring withdrawal/discontinuation of study medication · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma

Clobazam showed no clear difference in adverse effects requiring withdrawal/discontinuation of study… compared with phenytoin (low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Adverse effects: EPS: parkinsonism measured by average ESRS change scores · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

FATTY ACID ‐ ETHYL‐EPA showed no clear difference in adverse effects: EPS: parkinsonism measured by average ESRS change… compared with PLACEBO (low certainty).

1 finding from 1 review

ZOTEPINE vs REMOXIPRIDE

Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · patients with schizophrenia

ZOTEPINE showed no clear difference in adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with REMOXIPRIDE (low certainty).

1 finding from 1 review

ZOTEPINE vs CLOZAPINE

Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · patients with schizophrenia

It is very uncertain whether ZOTEPINE changes adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with CLOZAPINE (very low certainty).

1 finding from 1 review

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs antipsychotics

Adverse events: Specific: Weight gain ‐ all doses of depot risperidone ‐ short term Spontaneous reporting by study participants · patients with schizophrenia

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG may leads to lower specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight… compared with ANY ANTIPSYCHOTIC DRUG (low certainty).

1 finding from 1 review

Traditional suburethral sling operation vs open abdominal retropubic suspension

Long‐term adverse effects Number of women with recurrent UTIs at > 5 years · women with urinary incontinence

Traditional suburethral sling operation showed no clear difference in long‐term adverse effects Number of women with recurrent UTIs at > 5… compared with open abdominal retropubic colposuspension (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).

1 finding from 1 review